Ad
JAZZ Short Information Jazz Pharmaceuticals plc
home / stock / jazz / jazz short
Short Information | Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 3,717,517 |
| Total Actual Volume | 15,245,684 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 185,876 |
| Average Short Percentage | 24.33% |
Is there a JAZZ Short Squeeze or Breakout about to happen?
See the JAZZ Short Analysis for free Sign up or Login
Powered by Squeeze Report
JAZZ Twenty Trading Day's Volume to Short Volume Chart
JAZZ Twenty Trading Day Price Chart
JAZZ Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 06-18-2025 | $106.94 | $108.24 | $109.43 | $106.56 | 601,585 | 137,754 | 22.9% |
| 06-17-2025 | $108.15 | $107.05 | $109.3 | $106.62 | 539,621 | 165,567 | 30.68% |
| 06-16-2025 | $108.76 | $109.64 | $110.06 | $107.82 | 592,970 | 136,194 | 22.97% |
| 06-13-2025 | $108.65 | $108.5 | $110.04 | $108.02 | 478,132 | 133,604 | 27.94% |
| 06-12-2025 | $110.945 | $110.295 | $111.45 | $109.48 | 673,509 | 129,485 | 19.23% |
| 06-11-2025 | $113.18 | $110.5 | $113.59 | $109.74 | 847,398 | 194,887 | 23% |
| 06-10-2025 | $111.91 | $113 | $114.3 | $111.33 | 724,717 | 182,390 | 25.17% |
| 06-09-2025 | $111.25 | $111.87 | $113.1499 | $110.24 | 588,499 | 162,852 | 27.67% |
| 06-06-2025 | $110.17 | $111.13 | $111.84 | $108.93 | 726,525 | 154,095 | 21.21% |
| 06-05-2025 | $109.89 | $108.8 | $110.8999 | $108.46 | 637,539 | 125,981 | 19.76% |
| 06-04-2025 | $110.83 | $109.45 | $112.29 | $109.42 | 532,980 | 100,942 | 18.94% |
| 06-03-2025 | $108.81 | $110.32 | $110.78 | $107.605 | 702,129 | 156,003 | 22.22% |
| 06-02-2025 | $108.175 | $108.29 | $109.38 | $106.645 | 1,026,577 | 283,555 | 27.62% |
| 05-30-2025 | $107.7 | $108.07 | $108.62 | $105.38 | 977,559 | 169,483 | 17.34% |
| 05-29-2025 | $108.16 | $108.26 | $109.58 | $107.365 | 826,446 | 210,940 | 25.52% |
| 05-28-2025 | $109.41 | $107.01 | $109.6 | $106.69 | 706,810 | 171,322 | 24.24% |
| 05-27-2025 | $109.955 | $109.46 | $110.477 | $107.28 | 1,188,104 | 255,703 | 21.52% |
| 05-23-2025 | $106.01 | $108.07 | $109.3 | $106.01 | 958,802 | 316,885 | 33.05% |
| 05-22-2025 | $108 | $107.815 | $110.8 | $107.09 | 861,091 | 251,230 | 29.18% |
| 05-21-2025 | $110.1 | $108.27 | $112 | $108.04 | 1,054,691 | 278,645 | 26.42% |
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
0.11% G/L:
$107.51 Last:
1,053,609 Volume:
$108.12 Open:
$107.51 Close:
Jazz Pharmaceuticals plc Website:
Ad
-
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer PR Newswire Target Action (PDUFA) Date set for October 7, 2025 Application ...
-
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 PR Newswire First presentation of the Phase 4 XYLO switch study reports blood press...
-
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer PR Newswire First-line maintenance combination therapy redu...